Abstract: The disclosure provides a disease classification method and a disease classification device. The disease classification method includes: inputting samples into a first stage model and obtaining a first stage determination result; inputting first samples determined positive by the first stage model into a second stage high specificity model to obtain second samples determined to be positive and third samples determined to be negative and rule in the second samples; inputting fourth samples determined negative by the first stage model into a second stage high sensitivity model to obtain fifth samples determined to be positive and sixth samples determined to be negative and rule out the sixth samples; obtaining a second stage determination result of the second and sixth samples; and inputting the third and fifth samples not ruled in or ruled out into a third stage model and obtaining a third stage determination result of the third and fifth samples.

Abstract: The present invention provides a method for predicting a clinical prognosis of a subject having a cancer, especially a liver cancer, by measuring the expression level of at least one biomarker selected from the group consisting of B4GALT6, GLA, GM2A, HEXB and PSAP, and an upregulation of the at least one biomarker is indicative of the subject at increased risk for having a poor clinical prognosis.

Abstract: Disclosed are an anti-freezing agent for protecting a biological tissue from being damaged during a freezing treatment and a preparation method therefor. The method for preparing the anti-freezing agent involves mixing ethylene glycol, water and dimethylsulfoxide homogeneously to form a matrix, and then slowly adding sodium polyacrylate. The prepared anti-freezing agent is coated onto biological tissue during a freezing treatment such that damage to the biological tissue is reduced.

Abstract: The present disclosure provides an operating method of an automatic analysis system on magnetic resonance imaging (MRI), which includes steps as follows. Images are received from of the subject's brain from the MRI machine. Contrast-enhanced T1-weighted images and T2-weighted images are obtained from the images, and the pre-processing is performed on the images. The ratio of T2-weighted images to contrast-enhanced T1-weighted images is calculated to generate contrast-enhanced images. The unsupervised clustering is performed on the region of interest in the contrast-enhanced image to separate a cystic part and a non-cystic part so as to calculate the feature parameters. After radiosurgery is performed on the brain tumor corresponding to the region of interest, the volume change of the tumor is analyzed. The linear regression analysis of the feature parameters and the volume change of the tumor is performed for prognostic evaluation.

Abstract: A system for analyzing brain tissue components based on magnetic resonance image. The system includes a memory and a processor. The memory stores instructions. The processor accesses and executes the instructions to perform the following: extracting maps of tissue from a brain magnetic resonance imaging (MRI) corresponding to normal subjects; averaging the maps of tissue according to a number of the normal subjects to generate reference maps that correspond to different tissues; receiving a brain MRI sample having a targeted region; and analyzing the brain MRI sample based on the reference maps and the targeted region to generate an analysis result, in which the analysis result indicates a ratio of tissues in the targeted region of the brain MRI sample.

Abstract: Disclosed are an anti-freezing agent for protecting a biological tissue from being damaged during a freezing treatment and a preparation method therefor. The method for preparing the anti-freezing agent involves mixing ethylene glycol, water and dimethylsulfoxide homogeneously to form a matrix, and then slowly adding sodium polyacrylate. The prepared anti-freezing agent is coated onto biological tissue during a freezing treatment such that damage to the biological tissue is reduced.

Abstract: The present disclosure relates to methods, apparatuses, and computer programs for processing computed tomography images. Precise segmentation of the left atrium (LA) in computed tomography (CT) images constitutes a crucial preparatory step for catheter ablation in atrial fibrillation (AF). We aim to apply deep convolutional neural networks (DCNNs) to automate the LA detection/segmentation procedure and create a three-dimensional (3D) geometries. The deep learning provides an efficient and accurate way for automatic contouring and LA volume calculation based on the construction of the 3D LA geometry. Non-pulmonary vein (NPV) trigger has been reported as an important predictor of recurrence post atrial fibrillation (AF) ablation. Elimination of NPV triggers can reduce the post-ablation AF recurrence. The deep learning was applied in pre-ablation pulmonary vein computed tomography (PVCT) geometric slices to create a prediction model for NPV triggers in patients with paroxysmal atrial fibrillation (PAF).

Abstract: The invention provides an animal model for hepatocellular carcinoma and uses thereof. The genome of the animal model includes a hepatitis B virus genome and a single set of endogenous miR-122 that is partially deleted. Due to the early and high incidence of spontaneous hepatocellular carcinoma in the animal model and its abnormal fat metabolism, the animal model can be used to screen candidate agents for prevention or treatment of hepatitis B virus and hepatocellular carcinoma or other diseases or to develop uses for diagnosis and prediction of hepatocellular carcinoma.

Abstract: The present invention provides a carboxylated nanodiamond-mediated CRISPR-Cas9 delivery system for gene editing comprising nanodiamond (ND) particles as the carriers of CRISPR-Cas9 components designed to introduce the mutation in a given gene for repairing a tissue damage.

Abstract: The preset invention relates to a novel super-enhancer-bound Ash2l/OSN complex that can drive enhance activation, govern pluripotency network and stemness circuitry, and a reprogramming system or method through the regulation of this super-enhancer, Ash2l, to modulate pluripotency and cell fates. Ash2l directly binds to super-enhancers of several stemness genes to regulate pluripotency and self-renewal in pluripotent stem cells. Ash2l recruits Oct4/Sox2/Nanog (OSN) to form Ash2l/OSN complex at the super-enhancers of Jarid2, Nanog, Sox2, and Oct4, and further drives enhancer activation, upregulation of stemness genes, and maintains the pluripotent circuitry. Ash2l knockdown abrogates the OSN recruitment to all super-enhancers and further hinders the enhancer activation. In addition, CRISPRi/dCas9-mediated blocking of Ash2l-binding motifs at these super-enhancers also prevents OSN recruitment and enhancer activation, validating that Ash2l directly binds to super-enhancers and initiates the pluripotency network.

Abstract: The invention is a simplified model on kidney rejection in animals and its setting approach. The method involves isolating dendritic cells from male mice and isolating T cells from female mice and then using the naive T cells in vitro to culture concurrently with male dendritic cells. Those activated T cells from female origin were injected into renal cortex in male mice for the purpose of attacking renal cortex. The animal model simulates the renal transplant rejection method to enable effective induction of renal transplant immune reaction.

Abstract: The preset invention relates to preventing, arresting, reversing or treating atherosclerosis, comprising a step of: administering to a subject in need thereof a therapeutically effective amount of a macrophage inflammatory protein-1 beta (MIP-1?) inhibitor.

Abstract: The disclosure of the preset invention relates to a new method for preventing or treating tumor progression or tumor recurrence comprising administering to a subject in need thereof a therapeutically effective amount of an agent disrupting Musashi-1 (MSI1)/Argonaute 2 (AGO2) interaction. A composition or pharmaceutical composition for preventing or treating tumor progression or tumor recurrence is also provided, which comprises an agent disrupting Musashi-1 (MSI1)/Argonaute 2 (AGO2) interaction.

Abstract: Disclosed are an anti-freezing agent for protecting a biological tissue from being damaged during a freezing treatment and a preparation method therefor. The method for preparing the anti-freezing agent involves mixing ethylene glycol, water and dimethylsulfoxide homogeneously to form a matrix, and then slowly adding sodium polyacrylate. The prepared anti-freezing agent is coated onto biological tissue during a freezing treatment such that damage to the biological tissue is reduced.

Abstract: The present disclosure provides a magnetic resonance (MR) image analysis method for a patient who underwent radiotherapy. The method includes the steps: receiving an MR image set of a patient and a dose map of a radiotherapy plan; converting the dose intensity distribution of the dose map into the relative spatial positions in the MR image set; selecting a radiation dose and a radiation exposure region, wherein the radiation exposure region has radiation intensity being equal to or higher than the radiation dose; using the radiation exposure region to determine a region of interest (ROI) in the MR image set; classifying the voxels inside the ROI of the MR image set into different clusters according to the grayscale values of the voxels inside the ROI; and calculating the volume or ratios of the different clusters inside the ROI. The present disclosure also provides a method for evaluating risks of radiotherapy.

Abstract: A new approach for the treatment of a malignant disease is provided. The new method comprises administering a traditional anti-cancer therapy in combination with a DNA or protein vaccine comprising CTLA-4 and PD-1, or a DNA or protein vaccine comprising CTLA-4 and PD-L1.

Abstract: The present invention pertains to a new approach for the treatment of infectious and malignant diseases. The present invention provides new DNA and protein vaccines for the treatment of infectious and malignant diseases through enhancing immune response.

Abstract: Novel N-substituted norcantharimide derivatives are disclosed herein. The novel N-substituted norcantharimide derivatives are useful as lead compounds for manufacturing a medicament or a pharmaceutical composition for treating cancer, particularly for treating leukemia.

Abstract: The present invention pertains to a new approach for the treatment of infectious and malignant diseases. The present invention provides new DNA and protein vaccines for the treatment of infectious and malignant diseases through enhancing immune response.

Abstract: The present invention is based on the findings that a novel function for miR142-3p in the regulation of Sox2, adenylyl cyclase 9 (AC9), and CD133 expressions, and consequently the overall stemness of recurrent GBM cells as well as CSCs, and that miR142-3p modulated tumor-initiating properties in recurrent GBM. The present invention consequently supports the development of novel miRNA-based strategies for brain tumor treatment.